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Background: A Giardia outbreak was associated with development of post-infectious functional gastrointestinal
disorders (PI-FGID) and chronic fatigue syndrome (PI-CFS). Markers of immune dysfunction have given conflicting
results in CFS and FGID patient populations. The aim of this study was to evaluate a wide selection of markers of
immune dysfunction in these two co-occurring post-infectious syndromes.
Methods: 48 patients, reporting chronic fatigue in a questionnaire study, were clinically evaluated five years after
the outbreak and grouped according to Fukuda criteria for CFS (n=19) and idiopathic chronic fatigue (n=5) and
Rome II criteria for FGIDs (n=54). 22 Giardia exposed non-fatigued individuals and 10 healthy unexposed individuals
were recruited as controls. Peripheral blood lymphocyte subsets were analyzed by flow cytometry.
Results: In peripheral blood we found significantly higher CD8 T-cell levels in PI-FGID, and significantly lower
NK-cell levels in PI-CFS patients. Severity of abdominal and fatigue symptoms correlated negatively with NK-cell
levels. A tendency towards lower T-cell CD26 expression in FGID was seen.
Conclusion: Patients with PI-CFS and/or PI-FGID 5 years after Giardia lamblia infection showed alterations in NK-cell
and CD8-cell populations suggesting a possible immunological abnormality in these conditions. We found no
significant changes in other markers examined in this well-defined group of PI-CFS and PI-FGID elicited by a
gastrointestinal infection. Controlling for co-morbid conditions is important in evaluation of CFS-biomarkers.
Keywords: Giardia lamblia, Functional gastrointestinal disorder, Chronic fatigue syndrome, Irritable bowel
syndrome, NK-cells, CD8 T-cellsBackground
Infection with the intestinal protozoan parasite Giardia
lamblia is common in developing countries and is often
seen in travelers returning from endemic areas [1]. It is
also a frequent cause of waterborne outbreaks in indus-
trialized countries, but it is generally regarded as an un-
complicated infection for which there is effective
antibiotic treatment. Although long term abdominal
symptoms following acute giardiasis have been observed
by clinicians in individual patients for decades, studies* Correspondence: kurt.hanevik@med.uib.no
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(FGID) [2] and chronic fatigue [3] have only recently
been reported after a waterborne outbreak in Bergen in
2004 [4].
FGID are a group of disorders characterized by recur-
ring or chronic gastrointestinal symptoms without an
identifiable disease process [5]. Irritable bowel syndrome
(IBS) and functional dyspepsia (FD) are the best
described FGID. Fatigue is a frequent symptom in FGID
patients [3,6]. One study has found that 14% of IBS
patients also have chronic fatigue syndrome (CFS), while
six studies report that 35-92% of CFS patients also have
IBS [7]. Researchers of FGID as well as CFS [8,9] rarely
control for this co-morbidity, even though they are fo-
cusing on the same pathophysiologic mechanisms, suchl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neuroendocrine dysfunction, sensory hypersensitivity,
sustained stress responses and adverse life events under-
lying the symptomatology. FGID and CFS share the
characteristics of female preponderance, both are diag-
noses relying on symptom criteria alone, and in many
cases the onset is preceded by an acute infection [10].
Many studies have been reported regarding differ-
ences in activation and function in peripheral blood
lymphocyte subsets in CFS. These have given inconsist-
ent results, and are reviewed by Natelson et al., with
some studies finding altered natural killer (NK)-cell
levels and some finding lowered CD4:CD8 ratios, but
most studies find normal T, B and NK cell levels in CFS
[11]. More recent studies have reported a decrease in
the CD56brightCD16- NK-cell subset and increased
CD4CD25FoxP3 regulatory T-cells [12], and CD26
expressed on T-cells and NK-cells (marked with CD2)
has been put forward as a promising biomarker in
CFS [13].
Studies looking at peripheral blood lymphocyte subsets
in FGID have not identified differences in regulatory T-
cells [14] or lymphocyte subsets, but have found increased
levels of B-cells expressing IgG or co-stimulatory mole-
cules CD80 or CD86 and T-cells expressing β7+HLADR+
and CD69+ in IBS-patients compared to controls [15-17].
When the onset of FGID or CFS is associated with an
acute infection, it is often termed post-infectious CFS (PI-
CFS) [18,19] or FGID (PI-FGID) [20] or in the case of IBS,
post-infectious IBS (PI-IBS) [9]. A meta-analysis of PI-IBS
estimates that the risk of having IBS one year after an
acute gastroenteritis is approximately sixfold [21]. Until
recently few studies of FGID and CFS separated between
infection-related onset and a less defined onset in these
disorders.
The immune responses to Giardia infection are
known to include both innate and adaptive compo-
nents [22]. Important roles have been shown for
mast cells and IL-6 [23], as well as for B-cell anti-
body production [24,25]. In mice αβ-TCR-expressing
T-cells are required to control infection [26] and
CD4 T-cell depletion results in chronic infection
[27]. CD8 T-cells seems not to be important for the
control of infection in mice, but contribute to the
giardiasis related intestinal mucosal injury [28]. Beige
mice, which are deficient in NK-cells, have been
shown to clear Giardia infection equally fast as im-
munocompetent mice [29].
The present study, performed in a well-defined group
of patients with clinically observed post-infectious
FGID and CFS after a common eliciting Giardia infec-
tion, was done to evaluate a wide array of lymphocyte
subsets, including many of the previously reported
markers of immune dysfunction in CFS and FGID.Methods
Study population
In 2007, three years after a Giardia outbreak in Bergen,
Norway, 1252 persons with stool-microscopy confirmed
Giardia infection during the outbreak received a ques-
tionnaire regarding fatigue and abdominal complaints
[3]. Five years after the outbreak, in 2009, 253 persons
reporting chronic fatigue in the previous study received
a mailed invitation, and 53 of these chose to participate
in the present study, see Figure 1. These patients went
through a clinical evaluation and were screened with a
battery of routine blood tests. A total sample size of 50
was required for comparing two groups to obtain statis-
tically significant results with a power of 80% with stan-
dardized effect size of 1 and alpha of 0.01. Due to the
stratification of the patient population through clinical
evaluation and questionnaires, we included the 53
patients willing to participate. The control group of 30
sex and age matched individuals included 22 Giardia
exposed, non-fatigued questionnaire respondents and 10
healthy Giardia unexposed individuals. All were HIV
negative and were not taking immunomodulatory or
antibiotic medications. Written consent was obtained
from the participants. The study was approved by the
Regional Committee for Ethics in Medical Research and
the Norwegian Social Society Data Services in Bergen,
Norway.
Sampling
Patient and control blood samples for exclusion of other
diseases and for the purpose of this study were drawn
once between 08am and 09am after overnight fast and
analyzed in parallel during the same period. Fecal sam-
ples were screened by microscopy and 18S PCR [32] of
feces to rule out chronic giardiasis.
Questionnaires
On the day the blood samples were drawn, both patients
and controls completed a Rome II questionnaire [5] enab-
ling the classification of abdominal symptoms into IBS
and FD or other FGID. An abdominal symptom scoring
form was used to quantify abdominal symptoms [33].
Questions about abdominal complaints before the Giardia
infection enabled identification of post-infectious FGIDs.
To evaluate severity of fatigue, patients and controls also
completed the Fatigue Questionnaire [30], a validated set
of 11 questions addressing different aspects of fatigue.
FGID and fatigue categorization for analysis
Patients and controls were classified according to the
Rome II questionnaire with regard to FGID. Patients
were clinically evaluated once, but in separate consulta-
tions with specialists in internal medicine, psychiatry
and neurology. They were classified as PI-CFS or PI-
Figure 1 Study recruitment base and participants. Participants were recruited based on a mailed questionnaire study regarding fatigue [30]
and abdominal complaints [31] to all individuals with outbreak related laboratory confirmed giardiasis [3]. Five years after the outbreak, patients
who reported chronic fatigue in this questionnaire were invited to participate in a thorough clinical evaluation and screening. Fifty three
individuals agreed to participate. Five patients were excluded from this study after evaluation. Two control groups were recruited; 22 individuals
with normal score (=11) in the questionnaire three years after, and 10 healthy individuals not affected by the outbreak (unexposed controls) and
without particular abdominal symptoms or fatigue.
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Fukuda criteria [34], or as “fatigue other causes” when
most plausibly due to other co-morbidities, or as “fatigue
recovered” for individuals who had fully recovered from
the fatigue (Morch et al., submitted).
Three different categorizations of patients and controls
were formed for the analyses of the relative importance
of CFS and FGID co-morbidity on immunological vari-
ables; a fatigue categorization, a FGID categorization
and a combined categorization (Table 1). In the fatigue
categorization, exploratory analyses of lymphocyte sub-
sets in the small group of patients with PI-ICF (n=5)
showed similarities with the PI-CFS group. The two
groups were therefore analyzed together unless other-
wise clearly stated.
Regarding the FGID categorization, a number of patients’
symptoms did not match either the FD or the IBS criteria.
These would qualify for the less well-defined FGID like
functional bloating, functional diarrhea, functional abdom-
inal pain and unspecified functional bowel disorder. For
simplicity they were termed “other FGID”, and in some
analyses they were grouped together with the IBS and FD
groups forming an “all FGIDs” group. Three individuals
had both FD and IBS and were grouped as IBS in the ana-
lysis. Some exposed non-fatigued controls also had FGID
and were put together with the FGID group in some ana-
lyses. Seven of the participants had FGID-like abdominal
symptoms also before their Giardia infection. In someanalyses these were taken out in order to analyze PI-IBS
and PI-FGID specifically.
In the analyses we also set up a combined categorization
with one group of participants who had both FGID and
CFS/ICF, one group who had FGID only, and one group
with fatigue other cause with or without FGID. These
groups were compared to each other and to healthy con-
trols with neither FGID nor fatigue.
Lymphocyte quantification
Lymphocyte subpopulation quantification was per-
formed using the BD Multitest 6-color TBNK kit with
BD Trucount Tubes for relative and absolute concentra-
tion determination (BD Biosciences, San Jose, CA, USA).
The samples were prepared according to the manufac-
turer’s instructions and analyzed on a BD Canto II flow
cytometer (BD Biosciences).
PBMC acquisition and immunophenotyping
Peripheral blood mononuclear cells (PBMC) were iso-
lated by density gradient separation from BD Vacutainer
Na-citrate CPT tubes (BD, Franklin Lakes, NJ, USA).
After harvesting, the PBMC were washed twice in PBS
and cell suspensions (50μl) were stained 30 minutes in
the dark using combinations of the following optimally
titrated fluorescent dye-conjugated antibodies anti-
CD8a-FITC, anti-CD27-FITC, anti-CD26-PE, anti-β7-
PE, anti-CD45RO-PE, anti-CD4-PerCP-Cy5.5, anti-
Table 1 Sex ratio and mean age in the different clinical groups after allocation of patients and controls according to
Rome II FGID groups [5] and Fukuda CDC criteria [34] for the three analysis categorizations used in the present study
Breakdown into recruited groups
Age (mean (SD)) Females
(%)
Total
participants,
n
Exposed patients,
fatigue at
3 years, n
Exposed controls,
no fatigue at
3 years, n
Unexposed,
healthy
controls, n
Fatigue categorization
no-fatigue 40.9 (11.7) 72 32 0 22 10
CFS 45.5 (9.1) 79 19 19 0 0
ICF 37.8 (8.9) 80 5 5 0 0
Fatigue other cause 45.5 (15.2) 100 12 12 0 0
Fatigue recovered 36.0 (9.6) 58 12 12 0 0
FGID categorization
no-FGID 41.8 (13.2) 78 26 5 11 10
All FGID 41.4 (10.8) 76 54 43 11 0
PI-FGID 40.8 (10.2) 76 45 36 9 0
IBS 41.7 (10.4) 80 30 27 3 0
PI-IBS 40.4 (10.4) 79 24 22 2 0
Other FGID 41.1 (11.5) 71 24 16 8 0
Combined categorization
no-FGID/no-fatigue 39.9 (12.5) 74 23 2 11 10
FGID&CFS/ICF 44.3 (9.4) 78 23 23 0 0
CFS, no-FGID 35.0 100 1 1 0 0
FGID, no-fatigue 39.1 (10.1) 62 21 10 11 0
Fatigue other cause w/wo FGID 45.5 (11.5) 100 12 12 0 0
Abbreviations: CFS: chronic fatigue syndrome, FGID: functional gastrointestinal disorder, ICF: idiopathic chronic fatigue, IBS: irritable bowel syndrome,
PI: post-infectious.
Subgroups of interest within each group are indicated by indents.
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PerCP-Cy5.5, anti-HLADR-PE/Cy7, anti-CD25-PE/Cy7
(BioLegend, SanDiego, CA, USA), anti-CD3-ECD
(Beckman Coulter, Brea, CA, USA) and anti-CD127-
PerCP-Cy5.5 (eBioScience, SanDiego, CA, USA). Appro-
priate isotype controls from the same manufacturer were
used at equal concentrations. After staining, cells were
washed once, resuspended in PBS-paraformaldehyde so-
lution (1%) and analyzed the same day using a Beckman
Coulter Cytomics FC 500 MPL flow cytometer. In a typ-
ical acquisition 7 × 104 lymphocytes (min 2.3 × 104, max
1.7 × 105) were collected. The collected data were ana-
lyzed with FlowJo 7.6 software (Tree Star Inc, Ashland,
OR, USA).
Statistical analysis
Unless otherwise stated, the data are presented as mean
(standard deviation (SD)). Chi-squared tests were used for
categorical comparisons between groups. Lymphocyte
subset data and stimulation indices were analyzed using
the Kruskal-Wallis test for all groups within eachcategorization and then Mann Whitney U test to compare
two groups. The General Linear Model was used for
multivariate analyses of possible interactions and con-
founding factors like sex and age on lymphocyte subset
levels and for correlations between these and symptom
scores. Due to multiple comparisons in lymphocyte subset
analyses and a high number of variables, we chose a nom-
inal significance level of 0.01. PASW 18 (SPSS Inc, Chicago,
Ill, USA) was used for statistical analysis.
Results
Data from 48 patients (mean age 42.3 years (11.5)
range19-68, females 79%), 22 exposed controls (mean
age 39.8 (10.5) range 26–66, females 73%) and 10 unex-
posed controls (mean age 43.3 (14.3) range 22–63,
females 76%) were analyzed in this study. All partici-
pated in lymphocyte quantification, but for logistical rea-
sons not all patients and controls had all immunological
tests done, numbers given in Figure 1. The numbers of
patients and controls allocated into the fatigue, FGID
and combined categorizations are shown in Table 1.
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male distributions between the groups in each
categorization.
Lymphocyte quantification
Peripheral blood lymphocyte subset results for the three
analysis categorizations are shown in Table 2. We found
the CD4:CD8 ratio to be reduced and the CD8 T-cell
percentage to be increased in the FGID groups com-
pared to the no-FGID control group. The same pattern
was seen in the combined categorization, with elevated
CD8 T-cell percentages and concentrations in both the
group with FGID&CFS/ICF and the FGID, no-fatigue
group.
As has been reported by others [35,36] the NK-cell per-
centage measurements were significantly affected by sex,
with men having higher levels than women (p=0.006).
NK-cell levels also increased with increasing age (p=0.033).
Correcting for this using multivariate analysis showed that
PI-CFS/ICF patients had a lower percentage of NK-cells
than the no-fatigue controls (p=0.005) when analyzing
within the fatigue categorization. Also in the combined
categorization the FGID&CFS/ICF patient group had lower
percentage (p=0.006) and concentration (p=0.045) of
NK-cells. The percentage and concentrations of CD3 andTable 2 Peripheral blood lymphocyte quantification
CD4:CD8
ratio
CD3CD4
(%)
CD3CD4
106
cells/L
no-fatigue controls
(n = 32)
2.43 (0.97) 51.1 (8.2) 990 (376)
PI-CFS/ICF (n=24) 2.05 (0.76) 50.5 (7.0) 939 (366)
PI-CFS (n = 19) 2.01 (0.77) 50.3 (6.9) 912 (296)
Fatigue other cause
(n=12)
2.37 (1.14) 51.9 (8.1) 1132 (543)
Fatigue recovered
(n=12)
1.80 (0.82)* 46.1 (10.3) 834 (318)
no-FGID (n=26) 2.74 (1.06) 53.3 (8.6) 1008 (363)
All FGID (n=54) 1.96 (0.75)** 48.9 (7.7)* 958 (415)
PI-FGID (n=45) 2.00 (0.78)** 49.2 (7.9)* 949 (418)
PI-IBS (n=23) 1.97 (0.91)** 49.5 (8.8) 988 (463)
no-FGID/no-fatigue
controls (n=23)
2.65 (1.05) 52.4 (8.8) 974 (380)
FGID&CFS/ICF
(n=23)
2.01 (0.75)* 50.2 (7.0) 923 (366)
FGID, no fatigue
(n=21)
1.82 (0.65)** 46.9 (8.5)* 924 (356)
Fatigue other cause
w/wo FGID (n=12)
2.37 (1.14) 51.9 (8.1) 1133 (543)
* p < 0.05 level compared to the control group (in italics) in each categorization.
** Significant at p<0.01 level compared to the control group (in italics) in its catego
*** Significant at p<0.001 level compared to the control group (in italics) in its cate
CD4:CD8 T-cells ratio, CD4 and CD8 T-cell subsets, CD16CD56 natural killer cells per
subgroups. All values are given as mean (SD). Data for the subgroups of PI-CFS, PI-FCD4 T-cells and CD19 B-cells were similar in all groups
tested.
A significant correlation was found between the fa-
tigue scores and abdominal symptom scores (R=0.421,
p<0.001). NK-cell percentage correlated significantly
with both fatigue scores (p=0.003) and with abdominal
symptom scores (p=0.003) (Figure 2) and so did NK-cell
concentrations with p=0.01 and p=0.009, respectively.
Levels of CD8 T-cells did not show any correlation with
symptoms.
Immunophenotyping
CD4 and CD8 T-cells were analyzed for expression of
activation markers HLA-DR, CD25, CD26, and CD27
and CD45RO. CD56+ NK-cells were analyzed for
CD26. CD19+ B-cells were analyzed for activation mar-
kers CD25, CD26 and CD27. Additionally, we analyzed
percentage of gut-homing integrin β7 positive T-cells,
B-cells and CD4+CD25++CD127neg T-regulatory cells.
The percentage of CD26 positive CD3 T-cells in the “all
FGID” group (78.5%(9.4)) was insignificantly decreased
compared to the control group without FGID (83.4%(6.4))
in multivariate analysis (p=0.036). We did not find any sig-
nificant differences along the FGID or CFS categorizations
regarding the percentage of CD56dim or CD56bright NK-CD3CD8
(%)
CD3CD8
106
cells/L
CD16CD56
(%)
CD16CD56
106
cells/L
22.9 (5.5) 440 (198) 11.7 (6.7) 210 (99)
27.0 (7.0) 497 (207) 7.5 (3.5)** 130 (54)**
27.5 (7.0)* 497 (200) 8.0 (3.6)* 138 (55)**
26.1 (10.4) 635 (531) 8.7 (4.6) 186 (139)
28.8 (9.1)* 545 (225) 10.6 (9.0) 203 (188)
21.1 (5.4) 394 (167) 11.3 (7.1) 192 (80)
27.6 (7.6)*** 555 (311)** 9.1 (5.6) 176 (129)
27.1 (7.35)** 537 (313)* 8.8 (5.4) 169 (122)
28.2 (7.1)** 592 (376)* 8.1 (5.0)* 157 (111)
21.5 (5.5) 389 (171) 11.8 (7.6) 194 (86)
27.3 (6.9)** 500 (211) 7.4 (3.5)** 127 (53)*
27.9 (7.3)** 548 (214)** 11.0 (7.0) 223 (156)
26.1 (10.4) 635 (531) 8.7 (4.6) 186 (140)
rization.
gorization.
centages and concentrations by analysis categorizations and relevant
GID and PI-IBS are also given (indented).
Figure 2 NK-cell levels and symptoms correlations. Correlation plots between the percentage of peripheral blood CD16CD56 NK-cells and
fatigue symptom score (A) as recorded by the fatigue questionnaire [30] and total abdominal symptoms score (B) (including the six symptoms
nausea, early satiety, bloating, abdominal pain, constipation and diarrhoea, where patients graded their symptoms on an ordinal scale from 0 to
10 with 0 = no symptoms and 10 = severe symptoms).
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subsets. Nor did we find any significant differences be-
tween groups for activation markers and memory markers
in T-cells, B-cells or in the percentage of gut-homing integ-
rin β7 positive T-cells and B-cells or CD4+CD25++CD127-
Treg cells (data not shown).Discussion
In this study we classified patients and controls with FGID
according to Rome II criteria and by the Fukuda CDC cri-
teria for CFS and ICF regarding fatigue. A wide range of
peripheral blood lymphocyte subsets reported to be altered
in CFS and FGID were analyzed.CD8 T-cells and CD4:CD8 ratio
Searching the literature regarding CD4 and CD8 T-cell
subsets in FGID we found two studies which did not finddifferences in these T-cell subsets [15,16] and two studies
with lowered CD4/CD8 ratio in IBS patients; one due to
high total CD8 cells [37] and one due to low CD4 cells
[38]. While CD4 and CD8 T-cell numbers and percentages
may fluctuate considerably within an individual over time,
the CD4:CD8 ratio is found to be relatively stable [39]. We
found the CD4:CD8 ratio to be low due to increased CD8
T-cell numbers in our PI-FGID study population. Similar
peripheral blood T-cell patterns are reported in patients
suffering from a number of viral diseases like mononucle-
osis, dengue, RSV and cytomegalovirus infection and herpes
simplex recrudescence as well as in chronic toxoplasmosis
infection [39,40]. A low grade ongoing immune response
against reactivated viruses is a hypothesis of CFS morbidity
[41].
Without controlling for FGID co-morbidity, and in-
cluding the small group of patients recovered from fa-
tigue, the elevated CD8 levels might be interpreted as
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of the co-morbidity, the elevated CD8 level was seen to
be a feature of PI-FGID, rather than PI-CFS. Whether
the finding is a cause or effect of the Giardia induced
FGID needs further exploration.
CD8-T-cells have been shown to be responsible for the
mucosal injury and temporary loss of disaccharidase ac-
tivity in acute giardiasis [28]. Our finding of elevated
CD8 T-cell levels in post-giardiasis FGID patients may
indicate an association between the mucosal injury dur-
ing the acute infection and the observed prolonged
syndromes.
NK-cells in FGID and CFS
NK-cells do not seem to play a role in clearing acute
Giardia infection [29]. No previous study has evaluated
their possible role in post-giardiasis IBS or CFS. Two stud-
ies in general IBS populations found peripheral blood
CD56+ NK-cells levels to be similar to healthy controls
[16,42]. A post-prandial decrease in NK-cells in IBS patients
relative to controls has also been described [43].
The majority of studies of NK-cells in heterogeneous
CFS populations have not found differences in NK-cell
levels [11,12]. However, two studies have found signifi-
cantly reduced NK-cell levels in both PI-CFS and non-PI-
CFS patients [19,44]. One small study has shown NK-cell
levels to return to normal after successful recovery in the
PI-CFS group [45].
In our study, fatigue scores correlated with NK-cell
levels, and the patients who had recovered from chronic
fatigue showed NK-cell levels comparable to the non-
fatigue control group. These data suggest that decreased
NK-cell levels are associated with ongoing fatigue in
post-giardiasis PI-CFS. As we also found NK-cell levels
to be correlated with abdominal symptom scores, an al-
ternative explanation might be that NK-cell levels play a
role in sensitization or interpretation of sensory stimuli.
Activation markers and subsets
We could not replicate the elevated levels of CD26 expres-
sion in T and NK-cells as a robust marker of CFS reported
by Fletcher et al. [13]. Instead, there was a tendency to-
wards lower CD26+ T-cells in FGID patients.
A study in CFS patients recently reported higher levels
of CD4+CD25++FoxP3+ cells [12]. We found no difference
in regulatory T-cells with regard to fatigue categorization
as measured by CD4+CD25++CD127- cells, and also not
with regard to FGID categorization. Also a previous study
regarding regulatory T-cells in FGID patients did not find
any such difference [14].
Cautionary remarks
NK-cell levels are influenced by sleep and depression [46].
We did not control for poor sleep, but no patients in theCFS/ICF group had clinical depression. NK-cells are also
known to fluctuate considerably with exercise, but the
resting immune function evaluated in this study, is not
very different in athletes compared to non-athletes [47].
The cytotoxic activity of NK-cell has been more consist-
ently found decreased in CFS studies, but may be a by-
stander effect as it has been shown to be decreased in
chronic stress like unemployment, while NK-cell concen-
tration was not [48].
Out of the 253 invited persons, 53 consented to partici-
pate. We believe the main reason for the low participation
rate was that the basis for invitation to participate was fa-
tigue score at two years previously and that many had
recovered during this time span. Another reason may be
that the study logistics with five appointments for clinical
evaluations and testing was too demanding for some.
However, a chance for bias regarding increased health
seeking behavior in the participants cannot be excluded.
Also, we cannot fully exclude the contribution of an add-
itional viral trigger in the development or perpetuation of
fatigue symptoms.Conclusions
In the patients who developed PI-FGID and PI-CFS after
giardiasis, we found significantly increased CD8 T-cell
levels in patients with FGID and reduced levels of NK-cells
in CFS patients. There was a positive correlation between
fatigue scores and abdominal symptom scores in the study
population, and the severity of these symptom scores corre-
lated negatively with NK-cell levels. The findings suggest an
immunological abnormality in these patients and the po-
tential and relative importance of NK-cells and CD8 T-cells
in the co-morbid conditions FGID and CFS should be fur-
ther explored.
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